Semaglutide Research Guide

Full name: Semaglutide (GLP-1 Receptor Agonist)

A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Marketed as Ozempic/Wegovy. Achieves 15-17% body weight loss in clinical trials.

How Semaglutide Works

Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1.

Dosing Protocol

• Typical dose: 0.25 mg → titrate up to 2.4 mg
• Frequency: Once weekly
• Duration: Ongoing (chronic)
• Route: Subcutaneous injection

Reported Benefits

• Significant weight loss (15-17%)
• Improved glycemic control
• Cardiovascular risk reduction
• Reduced food cravings
• Lower HbA1c

Potential Side Effects

• Nausea and vomiting
• Diarrhea or constipation
• Abdominal pain
• Pancreatitis (rare)
• Gallbladder issues
• Muscle mass loss

Research Citations

1. STEP 1 Trial: Semaglutide 2.4mg for weight management (2021) - Participants lost mean 14.9% body weight vs 2.4% with placebo over 68 weeks with once-weekly injection.
2. SELECT cardiovascular outcomes trial with semaglutide (2023) - Semaglutide reduced major adverse cardiovascular events by 20% in overweight/obese adults without diabetes.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile
• Survodutide - Full Profile

View full Semaglutide profile with 3D molecule viewer →